Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PLEC | Q15149 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | GJA1 | P17302 | 1/20 | 0.44 |
| ▸ | GJB2 | P29033 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 11/20 | 0.42 |
| ▸ | CA1 | P00915 | 9/20 | 0.42 |
| ▸ | CA2 | P00918 | 9/20 | 0.42 |
| ▸ | CA12 | O43570 | 6/20 | 0.42 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29959958 | 1.00 | USP2 (0.52) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL12685866 | 0.85 | ESR1 (0.43) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL24855702 | 0.83 | USP2 (0.54) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL12382588 | 0.83 | USP2 (0.56) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL6694744 | 0.82 | USP2 (0.56) | USP2MEN1POLBKMT2AATM | |
| Hydrochloric Acid SCHEMBL2119295 | 0.82 | USP2 (0.55) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL22474769 | 0.79 | USP2 (0.49) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL29591827 | 0.78 | USP2 (0.76) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL107875 | 0.78 | USP2 (0.76) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL29781098 | 0.78 | USP2 (0.76) | USP2MEN1POLBKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103429256-B | Targeting of coagulation factors to TLT-1 on activated platelets | 诺和诺德保健股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11135275-B2 | Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets | NOVO NORDISK HEALTHCARE AG (CH) | 2021-10-05 | — | — | US | disclosed |
| US-11135275-B2 | Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets | NOVO NORDISK HEALTHCARE AG (CH) | 2021-10-05 | — | — | US | disclosed |
| EP-2680875-B1 | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS | NOVO NORDISK HEALTHCARE AG (CH) | 2019-10-23 | — | — | EP | disclosed |
| EP-2680875-B1 | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS | NOVO NORDISK HEALTHCARE AG (CH) | 2019-10-23 | — | — | EP | disclosed |
| US-20190083587-A1 | Coagulation factor-targeting to TLT-1 on activated platelets | NOVO NORDISK AS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-20190083587-A1 | Coagulation factor-targeting to TLT-1 on activated platelets | NOVO NORDISK AS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-20160263230-A1 | Coagulation Factor-Targeting to TLT-1 on Activated Platelets | NOVO NORDISK HEALTHCARE AG (CH) | 2016-09-15 | — | — | US | disclosed |
| US-20160263230-A1 | Coagulation Factor-Targeting to TLT-1 on Activated Platelets | NOVO NORDISK HEALTHCARE AG (CH) | 2016-09-15 | — | — | US | disclosed |
| US-20160263230-A1 | Coagulation Factor-Targeting to TLT-1 on Activated Platelets | NOVO NORDISK HEALTHCARE AG (CH) | 2016-09-15 | — | — | US | disclosed |
| US-20160251409-A1 | Targeted Delivery of Factor VIII Proteins to Platelets | NOVO NORDISK AS (DK) | 2016-09-01 | — | — | US | disclosed |
| US-20130337537-A1 | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS | NOVO NORDISK A/S (DK) | 2013-12-19 | — | — | US | disclosed |
| EP-2417155-B1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK AS (DK) | 2013-06-19 | — | — | EP | disclosed |
| EP-2417155-B1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK AS (DK) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012117091-A1 | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS | NOVO NORDISK A/S (DK) | 2012-09-07 | — | — | WO | disclosed |
| US-20120093840-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK A/S (DK) | 2012-04-19 | — | — | US | disclosed |
| US-20120093840-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK A/S (DK) | 2012-04-19 | — | — | US | disclosed |
| US-20120093840-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK A/S (DK) | 2012-04-19 | — | — | US | disclosed |
| WO-2010115866-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK A/S (DK) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083587-A1 | Coagulation factor-targeting to TLT-1 on activated platelets | TFPI, F13B, F3 | USP2 2685/4885MEN1 2343/4885POLB 1044/4885 |
| US-20120093840-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | F13B, F8, F13A1 | USP2 2998/4885MEN1 2770/4885POLB 2202/4885 |
| US-20160251409-A1 | Targeted Delivery of Factor VIII Proteins to Platelets | F13B, F8, F13A1 | USP2 2998/4885MEN1 2770/4885POLB 2202/4885 |
| US-11135275-B2 | Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets | TFPI, F3, F11 | USP2 3707/4885MEN1 1853/4885POLB 930/4885 |
| US-20160263230-A1 | Coagulation Factor-Targeting to TLT-1 on Activated Platelets | TFPI, F13B, F3 | USP2 2685/4885MEN1 2343/4885POLB 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.